Anna Maisa1
Christian Kollan1Matthias an der Heiden1
Florian van Bömmel2
Markus Cornberg3Stefan Mauss4
Heiner Wedemeyer3Daniel Schmidt1,5
Sandra Dudareva1*- 1Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
- 2Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany
- 3Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
- 4Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
- 5Charité Universitätsmedizin Berlin, Berlin, Germany
A Corrigendum on
Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
by Maisa, A., Kollan, C., an der Heiden, M., van Bömmel, F., Cornberg, M., Mauss, S., Wedemeyer, H., Schmidt, D., and Dudareva, S. (2021). Front. Public Health. 9:667253. doi: 10.3389/fpubh.2021.667253
In the original article, there was a mistake in the order of figures for Figures 1–3 as published. Figure 1 should be Figure 3, Figure 2 should be Figure 1, and Figure 3 should be Figure 2. The legends and references in the manuscript for all three figures were correct. The corrected Figures 1–3 appear below.
Figure 1. Number of chronic hepatitis B patients treated per month by drug, 2008–2019. The black line shows the cost per patient per month in Euro.
Figure 2. Proportion of prescriptions issued per year by prescription size, 2008–2019. P30–30 pills per prescription; P60–60 pills per prescription; P90–90 pills per prescription.
Figure 3. Prescriptions per 100,000 population by Federal State, Germany, 2008–2019.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: hepatitis B, nucleos(t)ide therapy, therapy costs, treatment guidelines, treatment gap, hepatitis elimination
Citation: Maisa A, Kollan C, an der Heiden M, van Bömmel F, Cornberg M, Mauss S, Wedemeyer H, Schmidt D and Dudareva S (2022) Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019. Front. Public Health 10:860836. doi: 10.3389/fpubh.2022.860836
Received: 23 January 2022; Accepted: 11 February 2022;
Published: 11 March 2022.
Edited and reviewed by: Zhiliang Hu, Nanjing Second Hospital, China
Copyright © 2022 Maisa, Kollan, an der Heiden, van Bömmel, Cornberg, Mauss, Wedemeyer, Schmidt and Dudareva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sandra Dudareva, ZHVkYXJldmFzQHJraS5kZQ==